Young Seok Kim

University of North Carolina at Chapel Hill, North Carolina, United States

Are you Young Seok Kim?

Claim your profile

Publications (295)611.91 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess the outcome of the treatment of primary vaginal cancer using definitive radiotherapy (RT) and to evaluate the prognostic factors of survival. Methods The medical records of nine institutions were retrospectively reviewed to find the patients with vaginal cancer treated with definitive RT with or without chemotherapy. A total of 138 patients met the inclusion criteria. None had undergone curative excision. Results The median follow-up time of the survivors was 77.6 months and the median survival time was 46.9 months. The 5-year overall survival, cancer-specific survival (CSS), and progression-free survival (PFS) rates were 68%, 80%, and 68.7%, respectively. In the survival analysis, the multivariate analysis showed that a lower the International Federation of Gynecology and Obstetrics (FIGO) stage and prior hysterectomy were favorable prognostic factors of CSS, and a lower FIGO stage and diagnosed prior to year 2000 were favorable prognostic factors of PFS. In the subgroup analysis of the patients with available human papillomavirus (HPV) results (n=27), no statistically significant relationship between the HPV status and recurrence or survival was found. Grade 3 or 4 acute and late toxicity were present in 16 and 9 patients, respectively. The FIGO stage and the tumor size were predictors of severe late toxicity. Conclusion The data clearly showed that a higher FIGO stage was correlated with a worse survival outcome and higher severe late toxicity. Therefore, precise RT and careful observation are crucial in advanced vaginal cancer. In this study, the HPV status was not related to the survival outcome, but its further investigation is needed. © 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
    Preview · Article · Mar 2016 · Journal of Gynecologic Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have designed and synthesized three emitters based on anthracene derivatives (1–3) containing various heterocyclic compounds via the Suzuki cross coupling reaction. Among those, a material showed efficient blue electroluminescent properties with a luminous, a power, and an external quantum efficiencies of 1.99 cd/A, 0.70 lm/W, and 1.17% at 20 mA/cm2, respectively.
    No preview · Article · Feb 2016 · Journal of Nanoscience and Nanotechnology
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we have designed and synthesized blue emitters based on quinoline-substituted 10-(naphthalene-7-yl)anthracene. Particularly, a material exhibited highly efficient blue electroluminescence with CIE coordinates of (0.15, 0.18).
    No preview · Article · Feb 2016 · Journal of Nanoscience and Nanotechnology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background & aim: To investigate the prevalence, mortalities, and patient characteristics of Acute-on-chronic liver failure (ACLF) according to the AARC (Asian Pacific Association for the Study of the Liver ACLF Research Consortium) and European Association for the Study of the Liver CLIF-C (Chronic Liver Failure Consortium) definitions. Methods: We collected retrospective data for 1470 hospitalized patients with chronic liver disease (CLD) and acute deterioration between January 2013 and December 2013 from 21 university hospitals in Korea. Results: Of the patients assessed, the prevalence of ACLF based on the AARC and CLIF-C definitions was 9.5% and 18.6%, respectively. The 28-day and 90-day mortality rates were higher in patients with ACLF than in those without ACLF. Patients who only met the CLIF-C definition had significantly lower 28-day and 90-day survival rates than those who only met the AARC definition (68.0% vs. 93.9%, P<0.001; 55.1% vs. 92.4%, P<0.001). Among the patients who had non-cirrhotic CLD, the 90-day mortality of the patients with ACLF was higher than of those without ACLF, although not significant (33.3% vs. 6.0%, P = 0.192). Patients with previous acute decompensation (AD) within 1- year had a lower 90-day survival rate than those with AD more than 1 year prior or without previous AD (81.0% vs. 91.9% or 89.4%, respectively, all P<0.001). Patients who had extra-hepatic organ failure without liver failure had a similar 90-day survival rate to those who had liver failure as a prerequisite (57.0% vs. 60.6%, P = 0.391). Conclusions: The two ACLF definitions result in differences in mortality and patient characteristics among ACLF patients. We suggest that non-cirrhotic CLD, previous AD within 1 year, and extra-hepatic organ failure should be included in the ACLF diagnostic criteria. In addition, further studies are necessary to develop a universal definition of ACLF.
    Full-text · Article · Jan 2016 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zoledronate (Zol) is a third-generation bisphosphonate that is widely used as an anti-resorptive agent for the treatment of cancer bone metastasis. While there is preclinical data indicating that bisphosphonates such as Zol have direct cytotoxic effects on cancer cells, such effect has not been firmly established in the clinical setting. This is likely due to the rapid absorption of bisphosphonates by the skeleton after intravenous (i.v.) administration. Herein, we report the reformulation of Zol using nanotechnology and evaluation of this novel nanoscale metal-organic frameworks (nMOFs) formulation of Zol as an anticancer agent. The nMOF formulation is comprised of a calcium zoledronate (CaZol) core and a polyethylene glycol (PEG) surface. To preferentially deliver CaZol nMOFs to tumors as well as facilitate cellular uptake of Zol, we incorporated folate (Fol)-targeted ligands on the nMOFs. The folate receptor (FR) is known to be overexpressed in several tumor types, including head-and-neck, prostate, and non-small cell lung cancers. We demonstrated that these targeted CaZol nMOFs possess excellent chemical and colloidal stability in physiological conditions. The release of encapsulated Zol from the nMOFs occurs in the mid-endosomes during nMOF endocytosis. In vitro toxicity studies demonstrated that Fol-targeted CaZol nMOFs are more efficient than small molecule Zol in inhibiting cell proliferation and inducing apoptosis in FR-overexpressing H460 non-small cell lung and PC3 prostate cancer cells. Our findings were further validated in vivo using mouse xenograft models of H460 and PC3. We demonstrated that Fol-targeted CaZol nMOFs are effective anticancer agents and increase the direct antitumor activity of Zol by 80-85% in vivo through inhibition of tumor neovasculature, and inhibiting cell proliferation and inducing apoptosis.
    No preview · Article · Jan 2016 · Biomaterials

  • No preview · Article · Jan 2016 · Journal of Gynecologic Oncology

  • No preview · Article · Dec 2015

  • No preview · Article · Dec 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: A prospective, randomized phase III, clinical trial was performed to assess treatment related acute toxicity, early response and survival difference, between a monthly 5-FU cisplatin, and a weekly cisplatin group alone, for concurrent chemoradiotherapy in the locally advanced uterine cervical carcinoma patients. MATERIALS AND METGODS: Between March 1998 and March 2000, 35 patients, with locally advanced (FIGO stage IIB to IVA) cervical carcinoma, were studied, but 5 patients were excluded inform the analysis due to their refusal of treatment. The patients were randomly assigned to 'monthly 5-FU cisplatin' (arm I), or 'weekly cisplatin' (arm II), groups. The patients of arm I received 5-FU cisplatin (5-FU 1,000 mg/m2/day cisplatin 20 mg/m2/day, IV continuous infusion, for 5 days, 3 cycles with 4-week intervals) with radiation therapy. Those of arm II received only cisplatin (cisplatin 30 mg/m2/day, IV bolus, 6 cycles with 1-week intervals) with radiation therapy. The radiation therapy consisted of external beam irradiation of 41.4~50.4 Gy/23~28 fractions, and high dose rate intracavitary treatments, delivering a dose of 30~35 Gy to point A in 6~7 fractions. During intracavitary radiation, a parametrial boost was delivered for a point B dose of 60 Gy in the non-thickened side, and 65 Gy in the thickened side. Treatment related acute toxicities were assessed using Radiation Therapy Oncology Group (RTOG) acute morbidity scoring criteria. The response to treatment, and survival, were analyzed. The median follow-up period was 19 months. Results: The FIGO stage distributions of arm I (n=16) and arm II (n=14) were as follows; IIB 10, IIIA 1, IIIB 4, IVA 1 in arm I, 12, 0, 1 and 1 in arm II respectively. The compliance of both arms were 80.0% and 93.3%, respectively (p=0.37). During radiation therapy, the incidences of leukopenia, greater than RTOG grade 2, were 25.0%, 14.3%, respectively. There were no patients with gastrointestinal or genitourinary toxicity greater than RTOG grade 2. The complete response rates at 3 months, following radiation therapy, were 87.5% and 92.9% respectively. Two-year disease free survival rates were 81.3%, 85.7%, respectively, for each arms. Conclusion: There was no significant difference in response to treatment, or patterns of failure, between the monthly FP and weekly cisplatin arms. Although there were no statistically significant differences, the patients of the weekly cisplatin arm had better compliance. More patients, and a longer follow up, are needed for improved evaluation of the regimen.
    Preview · Article · Dec 2015 · Cancer Research and Treatment
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we have synthesized phenyl-substituted triphenylene derivatives, using the Diels–Alder reaction and the Buchwald–Hartwig reaction. To investigate electroluminescence properties of these materials, multilayer organic light-emitting diode (OLED) devices were fabricated with a structure of indium–tin–oxide (ITO) (180 nm)/4,4′-bis(N-(1-naphthyl)-N-phenylamino)biphenyl (NPB) (50 nm)/blue-emitting materials (1–3) (30 nm)/bathophenanthroline (Bphen) (35 nm)/lithium quinolate (Liq) (2 nm)/Al (100 nm). A device using N2,N2,N11,N11,5,6,7-heptaphenyltriphenylene-2,11-diamine (2) exhibited efficient blue emission with luminous, power, and external quantum efficiencies of 0.92 cd/A, 0.67 lm/W, and 1.17% at 20 mA/cm2, respectively. The Commission International de L'Éclairage coordinates of this device were (x = 0.15, y = 0.09) at 6.0 V. Copyright
    No preview · Article · Dec 2015 · Luminescence
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three bispiro-type molecules, 2-(10-phenylanthracen-9-yl)-bispiro(9,10-dihydro-anthracene-9,7′-7′H-fluorene-10,7″-7″H-fluorene) (1), 10-([naphthalen-2-yl]anthracen-9-yl)-bispiro(9,10-dihydro-anthracene-9,7′-7′H-fluorene-10,7″-7″H-fluorene) (2), and 10-([naphthalen-1-yl]anthracen-9-yl)-bispiro(9,10-dihydro-anthracene-9,7′-7′H-fluorene-10,7″-7″H-fluorene) (3), were synthesized by Pt-catalyzed Suzuki coupling reactions. To explore electroluminescence properties of these materials, devices were fabricated with the following structures: Indium-tin-oxide (180 nm)/4,4′-Bis(N-(1-naphthyl)-N-phenylamino)biphenyl (60 nm)/blue emitting materials (30 nm)/Bathophenanthroline (30 nm)/Lithium quinolate (2 nm)/Al (100 nm). Among devices, device using 2-(10-phenylanthracen-9-yl)-bispiro(9,10-dihydro-anthracene-9,7′-7′H-fluorene-10,7″-7″H-fluorene) showed the efficient blue emission with a luminous efficiency of 1.57 cd/A, a power efficiency of 1.83 lm/W and an external quantum efficiency of 1.83% at 20 mA/cm2, respectively. The CIE coordinates of this device were (0.16, 0.10).
    No preview · Article · Dec 2015 · Dyes and Pigments
  • [Show abstract] [Hide abstract]
    ABSTRACT: Collagen IV-targeting peptide-conjugated basement membrane-targeting nanoparticles are successfully engineered to identify early-stage blood vessel injury induced by high-dose radiotherapy.
    No preview · Article · Nov 2015 · Small
  • [Show abstract] [Hide abstract]
    ABSTRACT: We demonstrated triphenylsilane-substituted arenes (1-4) as host materials for green phosphorescent organic light-emitting diodes. Particularly, a device using 9,9-dimethyl-2-(triphenylsilyl)-7-[4-(triphenylsilyl)phenyl]-9H-fluorene (compound 4) as the host material with the green phosphorescence dopant bis[2-(1,1′,2′,1′′-terphen-3-yl)pyridinato-C,N]iridium(III)(acetylacetonate) showed the efficient green emission with an external quantum efficiency of 4.64%, a power efficiency of 7.2 lm/W and luminous efficiency of 16.6 cd/A at 20 mA/cm2, respectively, with the Commission International de L'Eclairage chromaticity coordinates of (0.33, 0.59) at 8.0 V.
    No preview · Article · Nov 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Four 9,9-diethyl-N,N-diphenyl-9 H-fluoren-2-amine substituted anthracene derivatives have been designed and synthesized by Suzuki cross coupling reactions. To explore the electroluminescent properties of these blue materials, multilayer blue organic light-emitting diodes were fabricated in the following device structure: indium tin oxide (180 nm)/N,N’-diphenyl-N,N’-(1-napthyl)-(1,1′-phenyl)-4,4′-diamine (50 nm)/blue emitting materials (1–4) (30 nm)/bathophenanthroline (30 nm)/lithium quinolate (2 nm)/Al (100 nm). All devices appeared excellent deep-blue emissions. Among them, a device exhibited a maximum luminance of 5686 cd/m2, the luminous, power and external quantum efficiencies of 5.11 cd/A, 3.79 lm/W, and 4.06% with the Commission International de L'Eclairage coordinates of (0.15, 0.15) at 500 cd/m2, respectively.
    No preview · Article · Nov 2015 · Thin Solid Films
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: We evaluated the role of adjuvant therapy in stage IIIA endometrioid adenocarcinoma patients who underwent surgery followed by radiotherapy (RT) alone or chemoradiotherapy (CTRT) according to risk group. Materials and methods: A multicenter retrospective study was conducted including patients with surgical stage IIIA endometrial cancer treated by radical surgery and adjuvant RT or CTRT. Disease-free survival (DFS) and overall survival (OS) were analyzed. Results: Ninety-three patients with stage IIIA disease were identified. Nineteen patients (20.4%) experienced recurrence, mostly distant metastasis (17.2%). Combined CTRT did not affect DFS (74.1% vs. 82.4%, p=0.130) or OS (96.3% vs. 91.9%, p=0.262) in stage IIIA disease compared with RT alone. Patients with age≥60, grade G2/3, and lymphovascular space involvement had a significantly worse DFS and those variables were defined as risk factors. The high risk group showed a significant reduction in 5-year DFS (≥2 risk factors) (49.0% vs. 88.0%, P<0.001) compared with the low risk group (< 2). Multivariate analysis confirmed that more than one risk factor was the only predictor of worse DFS (HR, 5.45; 95% CI, 2.12-13.98; p<0.001). Of patients with no risk factors, a subset treated with RT alone showed an excellent 5-year DFS and OS (93.8% and 100%, respectively). Conclusion: We identified a low-risk subset of stage IIIA endometrioid adenocarcinoma patients who might be reasonable candidates for adjuvant RT alone. Further randomized studies are needed to determine which subset might benefit from combined CTRT.
    No preview · Article · Oct 2015 · Cancer Research and Treatment
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: We evaluated the prognostic factors and clinical outcomes of 56 patients with vulvar cancer treated with curative radiotherapy (RT) or concurrent chemoradiotherapy. Materials and methods: Overall survival (OS) and disease-free survival (DFS) were assessed retrospectively. Prognostic factors evaluated included age, International Federation of Gynecology and Obstetrics (FIGO) stage, TNM classification, tumor size, treatment modality, RT duration, and RT field. The association between the tumor human papillomavirus (HPV) status and survival was analyzed in 35 patients. Results: During the median follow-up of 2.8 years (range, 0.3 to 18.9 years), 21 patients (37.5%) experienced treatment failure. Fifteen patients (27%) had local failure: nine (16%) local failure only, three (5%) locoregional failure, two (4%) local and distant failure, and one (2%) locoregional and distant failure. Of 56 patients, seven (13%) had persistent disease at the first follow-up at 2 months and all but one died within a year after completing RT. The 5-year OS and DFS were 51.6% and 44.0%, respectively. In multivariate analysis, clinical size ≥3 cm predicted a poor prognostic factor for DFS (p = 0.040) and age (≥70 years) was poor prognostic for DFS (p = 0.032) and OS (p = 0.048). Patients with HPV-positive tumors tended to have better 5-year OS and DFS, but the differences were not significant statistically. Conclusion: Clinical size ≥3 cm was a significant prognostic factor for DFS. However, age was the most important prognostic factor for DFS and OS in patients treated with curative RT. Further studies are needed to determine which treatment should be considered for old age ≥70 years.
    Full-text · Article · Oct 2015
  • Young Seok Kim · Jong Hwan Kim · Il Gu Kim · Bong Ki Ryu
    [Show abstract] [Hide abstract]
    ABSTRACT: CeO2 is known as a universal catalyst, and most studies in the literature have concentrated on enhancing the properties of CeO2. In this study, we used amorphous CeCO2 to fabricate glass samples and determined their properties. Generally, the catalytic reactions of CeO2 involve redox reactions. To test the reactivity of these glass structures, coverage should increase beyond the limitations of the powder. Glass was chosen rather than conventional materials because it is highly stable and used in a variety of fields. Phosphate systems were selected to analyze the characteristics of the glass samples fabricated with various compositions, and the properties of the glass samples depended on the composition used to fabricate them. The relationship between the ionicity of CeO2 and the catalytic behavior of these systems was determined and analyzed.
    No preview · Article · Oct 2015 · Taehan-Kŭmsok-Hakhoe-chi = Journal of the Korean Institute of Metals and Materials

  • No preview · Article · Sep 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, we used the Suzuki cross-coupling reaction to synthesize the following two emitting materials: 1,3-bis(10-phenylanthracen-9-yl)benzene (1) and 2,6-bis(10-phenylanthracen-9-yl)pyridine (2). To investigate the electroluminescent (EL) properties of these materials, multilayered organic light-emitting diodes (OLEDs) devices were fabricated in the following sequence: indium-tin-oxide (ITO) (180 nm)/4,4′-bis(N-(1-naphthyl)-N-phenylamino)biphenyl (NPB) (50 nm)/emitting materials (1 and 2) (40 nm)/tris(8-hydroxyquinolinato)aluminium (Alq3) (15 nm)/lithium quinolate (Liq) (2 nm)/Al (100 nm). Of special significance, a device using 1 as an emitting material showed a white emission with maximum luminance, luminous, power, and external quantum efficiency values of 1727 cd/m2, 1.74 cd/A, 0.78 lm/W, and 0.67% at 20 mA/cm2, respectively, as well as CIE coordinates of (0.31, 0.44) at 7 V. Another device using 2 exhibited a sky-blue emission with maximum luminance, luminous, power, and external quantum efficiency values of 2279 cd/m2, 1.95 cd/A, 0.97 lm/W, and 0.93% at 20 mA/cm2, respectively as well as CIE coordinates of (0.24, 0.29) at 7 V.
    No preview · Article · Sep 2015 · Journal of Photochemistry and Photobiology A Chemistry
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study reports the emitting materials based on phenylanthracene-substituted naphthalene derivatives to achieve efficient electroluminescent properties for OLED applications. An OLED device using 4,4′-bis(10-phenylanthracen-9-yl)-1,1′-binaphthalene exhibited the blue emission with the CIE coordinates of (0.19, 0.16) and efficient electroluminescent properties with the luminance, power and external quantum efficiency of 1.70 cd/A, 0.79 lm/W and 1.26% at 20 mA/cm2, respectively. Also, the other device using 1,4-bis(10-phenylanthracene-9-yl)naphthalene exhibited white emission with the CIE coordinates of (0.34, 0.43) at 7 V, respectively. This device exhibits the luminance, power and external quantum efficiency of 2.22 cd/A, 1.13 lm/W and 0.86% at 20 mA/cm2, respectively.
    No preview · Article · Sep 2015 · Journal of Luminescence

Publication Stats

2k Citations
611.91 Total Impact Points


  • 2015-2016
    • University of North Carolina at Chapel Hill
      North Carolina, United States
    • Sejong University
      • Department of Electronic Engineering
      Sŏul, Seoul, South Korea
    • Asan Medical Center
      Sŏul, Seoul, South Korea
  • 2013-2015
    • Sungkyunkwan University
      • Department of Chemistry
      Sŏul, Seoul, South Korea
    • Hallym University
      Sŏul, Seoul, South Korea
    • Chungnam National University
      • Department of Family Medicine
      Daiden, Daejeon, South Korea
    • Korea Electronics Technology Institute
      • Display Components and Materials Research Center
      Sŏngnam, Gyeonggi Province, South Korea
  • 2012-2015
    • Seoul National University
      • Department of Materials Science and Engineering
      Sŏul, Seoul, South Korea
    • Korea Institute of Construction Technology
      Kōyō, Gyeonggi-do, South Korea
    • Keimyung University
      Daikyū, Daegu, South Korea
  • 2009-2015
    • Soonchunhyang University
      • College of Medicine
      Onyang, Chungcheongnam-do, South Korea
    • Korea Environmental Industry and Technology Institute
      Sŏul, Seoul, South Korea
    • Chung-Ang University
      • College of Medicine
      Sŏul, Seoul, South Korea
    • Chung-Ang University Hospital
      Sŏul, Seoul, South Korea
  • 2007-2015
    • Pusan National University
      • • Department of Nanomaterials Engineering
      • • Division of Materials Science and Engineering
      Busan, Busan, South Korea
  • 2003-2015
    • Soon Chun Hyang University Hospital
      • Department of Gastroenterology
      Sŏul, Seoul, South Korea
  • 2011-2014
    • Ulsan University Hospital
      Urusan, Ulsan, South Korea
  • 2010-2014
    • Yonsei University Hospital
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
  • 2009-2014
    • Wonju Severance Christian Hospital
      Genshū, Gangwon-do, South Korea
  • 2008-2014
    • Yonsei University
      • Department of Plastic & Reconstructive Surgery
      Sŏul, Seoul, South Korea
    • University of California, Davis
      Davis, California, United States
  • 2003-2014
    • University of Ulsan
      • • College of Medicine
      • • Department of Radiation Oncology
      Ulsan, Ulsan, South Korea
  • 2009-2010
    • University of Massachusetts Amherst
      • Department of Chemical Engineering
      Amherst Center, Massachusetts, United States
  • 2006-2010
    • Korea Institute of Industrial Technology
      Anzan, Gyeonggi Province, South Korea
    • University of Florida
      • Department of Chemical Engineering
      Gainesville, FL, United States
    • Gachon University
      • Gil Medical Center
      Seongnam, Gyeonggi, South Korea
  • 2006-2007
    • Inha University
      • Department of Chemistry
      Seoul, Seoul, South Korea
  • 2003-2005
    • Korea University
      • Department of Chemical and Biological Engineering
      Sŏul, Seoul, South Korea
  • 1996
    • Rensselaer Polytechnic Institute
      Troy, New York, United States